What is Apidra and What Does it Treat?
Apidra is a rapid-acting insulin used to manage blood sugar levels in adults and children with diabetes [1][2]. It works by lowering blood glucose levels and is typically administered before meals [2]. Apidra is a brand name for insulin glulisine [2].
When Does Apidra's Patent Protection End?
The patent for Apidra (insulin glulisine) has expired in major markets, meaning generic versions may become available [3]. DrugPatentWatch.com tracks these patent expirations to indicate when market exclusivity ends [3].
What Are the Different Forms of Apidra?
Apidra is available in a vial for injection [1]. It is also available in a SoloStar prefilled pen [1].
How Does Apidra Compare to Other Insulin Products?
Apidra is a rapid-acting insulin, meaning it starts working relatively quickly after injection, similar to other rapid-acting insulins like Humalog (insulin lispro) and Novolog (insulin aspart) [4]. These insulins are often used interchangeably or in combination with longer-acting insulins for basal coverage [4].
Who Manufactures Apidra?
Apidra is manufactured by Sanofi [1].
Where Can I Find More Information on Apidra's Patents?
DrugPatentWatch.com provides detailed information on drug patents, including those for Apidra, and their expiration timelines [3].
---
Sources:
[1] https://www.apidra.com/
[2] https://www.webmd.com/drugs/2/203061/apidra-oral-injection/details
[3] https://www.drugpatentwatch.com/
[4] https://www.goodrx.com/apidra